carboplatin + pemetrexed

**Carboplatin + pemetrexed** is an intravenous antineoplastic co-administration regimen composed of two small-molecule cytotoxic drugs. Carboplatin is a platinum coordination compound that forms covalent DNA adducts and intra- and interstrand crosslinks, disrupting DNA replication and transcription. Pemetrexed is a multitargeted antifolate antimetabolite that inhibits thymidylate synthase, dihydrofolate reductase, and phosphoribosylglycinamide formyltransferase, suppressing thymidine and purine nucleotide synthesis. The regimen has been investigated in breast cancer, esophageal cancer, small cell lung cancer, non-small cell lung cancer, and platinum-sensitive recurrent ovarian cancer. It is administered as separate products rather than as a single fixed-dose drug product; folic acid and vitamin B12 supplementation are commonly used with pemetrexed to reduce toxicity.

Brand names

Alimta

Other names

carboplatin + pemetrexedcarboplatin/pemetrexedpemetrexed + carboplatinpemetrexed-carboplatinpemetrexed/carboplatin